Jaguar Health to Integrate AI for Rare Disease Drug Development

Key Facts

1Jaguar Health plans to use AI platforms to enhance the development and commercialization of Crofelemer for intestinal failure (IF) programs.

2The global market for Short Bowel Syndrome, including Intestinal Failure, is estimated to reach $8.0 billion by 2033.

3The company is seeking FDA approval for MVID, a lethal pediatric orphan disease with no current alternative treatments.

Jaguar Health (NASDAQ: JAGX) has announced plans to leverage AI platforms to accelerate the development and commercialization of its drug, Crofelemer. The initiative specifically targets intestinal failure programs and aims to establish credible links between genetics and disease progression. The company is currently seeking FDA approval for the treatment of Microvillus Inclusion Disease (MVID), a lethal pediatric orphan disease with no existing alternatives. This strategic move positions Jaguar Health to capture a share of the Short Bowel Syndrome market, projected to reach $8 billion by 2033. By integrating AI, the firm expects to optimize personalized treatment regimens and enhance clinical data analysis for ultra-rare conditions. The adoption of advanced technology marks a significant milestone in the company's efforts to address high-value medical needs in the biotech sector.